Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimising acid inhibition treatment.

Fernando Gomollón1, Xavier Calvet

  • 1Facultad de Medicina, Gastroenterology Service, Clinical University Hospital, Zaragoza, Spain. fgomollon@gmail.com

Drugs
|December 13, 2005
PubMed
Summary

Proton pump inhibitors (PPIs) are highly effective acid inhibitors for various gastrointestinal conditions. Esomeprazole shows a slight advantage for potent acid inhibition in specific cases like refractory gastro-oesophageal reflux disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TIME-trend and forecasting of the economic impact of inflammatory bowel disease in Catalonia: a population-based analysis.

Journal of medical economics·2026
Same author

Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumab.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Prevalence, incidence and mortality of pediatric inflammatory bowel disease in Catalonia (EPIBDCat).

Revista espanola de enfermedades digestivas·2026
Same author

Development and validation of the inflammatory bowel disease objective disability index (IBDODI).

Revista espanola de enfermedades digestivas·2026
Same author

Microbial signatures in psoriatic arthritis distinguish disease phenotypes and newly diagnosed inflammatory bowel disease independent of faecal calprotectin.

Annals of the rheumatic diseases·2026
Same author

Hidradenitis suppurativa in patients with inflammatory bowel disease: a national multicenter study from the GETECCU-ENEIDA Registry.

Therapeutic advances in gastroenterology·2026

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Acid inhibition is a critical therapeutic strategy in managing diverse gastrointestinal disorders.
  • Proton pump inhibitors (PPIs) represent a class of drugs with superior efficacy compared to H2-receptor antagonists for acid suppression.

Purpose of the Study:

  • To outline the clinical utility and indications for potent acid inhibition using proton pump inhibitors.
  • To compare the effectiveness of PPIs and H2-receptor antagonists.
  • To highlight specific scenarios where PPIs are particularly beneficial and discuss optimal drug selection.

Main Methods:

  • Review of clinical evidence and guidelines regarding acid inhibition therapies.
  • Comparative analysis of proton pump inhibitors and H2-receptor antagonists.
  • Discussion of patient-specific factors influencing treatment decisions.

Main Results:

  • Proton pump inhibitors are indicated for Helicobacter pylori eradication, peptic ulcer healing, prevention/treatment of NSAID-induced lesions, bleeding peptic ulcers, and gastro-oesophageal reflux disease management.
  • PPIs demonstrate superior efficacy over H2-receptor antagonists across most clinical applications.
  • Esomeprazole exhibits a favorable pharmacological and clinical profile for potent oral acid inhibition, particularly in refractory GERD and Barrett's esophagus.

Conclusions:

  • Proton pump inhibitors are safe and effective for a wide range of acid-related gastrointestinal conditions.
  • Treatment strategies, including drug choice, dosage, and administration route, should be individualized.
  • Esomeprazole may offer advantages in specific clinical situations requiring potent acid suppression.

Related Experiment Videos